On April 03, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 5-10 in San Diego (Press release, Guardant Health, APR 3, 2024, View Source [SID1234641756]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Multiple poster sessions will report on the utility of using the Guardant Infinity platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction. Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen.
"We look forward to sharing new data at AACR (Free AACR Whitepaper), in particular studies demonstrating the potential for epigenomic analysis using the Guardant Infinity platform to advance cancer research," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "These presentations illustrate how epigenomics can unlock the mechanisms of cancer cell regulation that are invisible to genomic testing, allowing us to expand patient eligibility for clinical trials and contributing to targeted therapy development and better-informed patient care."
The Guardant Infinity smart liquid biopsy platform used in many of the studies combines genomic and epigenomic profiling to deliver multidimensional insights that allow researchers and clinicians to characterize and quantify cancer—in areas such as tumor heterogeneity, disease progression and treatment response. The epigenomic insights enable more personalized treatment strategies by increasing accuracy in minimal residual disease detection and monitoring through enhanced ctDNA detection and quantification, and by identifying new patients or predicting response to therapy through novel epigenomic biomarkers.
Full List of Guardant Health Presentations
Poster
Title
Product
Sunday, April 7 | 1:30 – 5:00 pm
406/6
Characterization of whole genome duplication in a genomic cohort of over 14000 cell free DNA samples
GuardantOMNI
969/10
Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2- breast cancer receiving first-line CDK4/6 inhibitor and endocrine therapy
Guardant Infinity
Monday, April 8 | 9:00 am – 12:30 pm
2390/5
Longitudinal assessment of circulating tumor DNA in patients with advanced colorectal cancer: A proposed general statistical framework and visualization tool
GuardantINFORM
2420/16
Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)
Guardant Reveal
2490/7
Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay
Guardant Infinity
Monday, April 8 | 1:30 – 5:00 pm
3499/21
Non-small cell lung cancer (NSCLC) histology classification using DNA methylation data captured from liquid biopsies
Guardant Infinity
3399/1
Prediction of cardiac adverse events (AE) in trastuzumab treated breast cancer patients (pts) via a comprehensive genomic and DNA methylation blood based assay
Guardant Infinity
3670/15
Reducing the patient burden for ctDNA biomarkers: Advancing small volume home-based collection technologies
Guardant360
Monday, April 8 | 3:05 – 3:20 pm Minisymposium – Oral Presentation
3888
TOP1 mutations mediate cross resistance to ADCs in metastatic breast cancer
GuardantOMNI
The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the AACR (Free AACR Whitepaper) website here.
For more information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit AACR (Free AACR Whitepaper) booth #3545.